US & Canada, Dec. 17, 2024 (GLOBE NEWSWIRE) — According to a new comprehensive report from The Insight Partners, the Global Cell Line Development Market is expected to reach US$ 18.62 billion by 2031 from US$ 6.86 billion in 2023; it is expected to register a CAGR of 13.3% during the forecast period. Cell line development is the process by which living cells manufacture therapeutic biologics or other proteins of interest. The development starts at small-scale suspension cultures, eventually transitioning to industrial-scale bioreactors at the manufacturing stage.
The report from The Insight Partners provides several stakeholders—including manufacturers, service providers, and end users—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities.
Access PDF Sample Cell Line Development Market Report (Including Graphs, Charts & Figures) – https://www.theinsightpartners.com/sample/TIPHE100001196/
Overview of Report Findings
- Increasing Adoption of Regenerative Medicines: Regenerative medicine replaces or heals tissues as well as organs damaged by age, disease, or trauma. The tissue engineering industry has emerged and evolved into the broader area of regenerative medicine. Regenerative medicine is a rapidly growing interdisciplinary field involving engineering sciences to develop clinical therapies intended to maintain, repair, replace, and enhance biological function. Cell line development is a crucial and invariable part of regenerative medicine that helps understand the treatment of injuries and diseases, from broken bones to neurodegenerative diseases. Thus, the rise in the adoption of regenerative medicines is expected to foster the demand for cell line development, thereby driving market growth. Cell development has multiple potential applications, including drug testing and development, cell-based therapy development, cancer tissue research, and others. New drugs developed in pharmaceutical companies could be safely and effectively tested using differentiated stem cells. Furthermore, regenerative medicines using cell-based models have the potential to help researchers in early intervention treatment for degenerative diseases and traumatic injuries. Thus, the above-mentioned applications of cell line development in regenerative medicines are expected to propel the global market growth over the coming years.
- Rising Prevalence of Cancer: Cancer cases have been increasing tremendously, and the trend is anticipated to remain the same in the upcoming years. Cancer is among the leading causes of death across the globe and is profoundly affecting the quality of life. Lifestyle changes have resulted in more exposure to oncogenic factors. For instance, as per the American Cancer Society, in 2020, there will be an expected 1.8 million new cancer cases detected and 606,520 cancer deaths in the US. According to the World Health Organization, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. Cancer can be cured if diagnosed and treated at an initial stage. Cancer sequencing using next-generation sequencing (NGS) methods provides detailed information. Moreover, cell line development aids in research, diagnostics, and treatment of cancer. Thus, cancer will be a burden on society if not diagnosed and treated on time.
- Geographic Insights: In 2023, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific. Asia Pacific is expected to record the highest CAGR during the forecast period.
| Report Attributes | Details | |
| Market Size in 2023 | US$ 6.86 Billion | |
| Market Size by 2031 | US$ 18.62 Billion | |
| CAGR | 13.3 | % |
| Base Year | 2023 | |
| Forecast Period | 2023-2031 | |
| Historical Data | 2021-2022 | |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe – [UK, Germany, France, Russia, Italy, Rest of Europe] Asia-Pacific – [China, India, Japan, Australia, Rest of Asia-Pacific] South and Central America [Brazil, Argentina, Rest of South and Central America] Middle East and Africa [South Africa, Saudi Arabia, UAE and Rest of Middle East and Africa] | |
Get a Customized Copy of the Cell Line Development Market Report – https://www.theinsightpartners.com/reports/cell-line-development-market
Market Segmentation
- Based on type, the cell line development market is segmented into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell line segment held the largest market share in 2023.
- By product, the cell line development market is categorized into equipment and media & reagent. The media & reagent segment led the market in 2023.
- In terms of application, the cell line development market is divided into drug discovery, bioproduction, and tissue engineering. In 2023, the bioproduction segment dominated the market with the largest market share.
- The cell line development market is segmented into five major regions: North America, Europe, APAC, the Middle East & Africa, and South & Central America.
Segments Covered
By Type
- Primary Cell Line
- Hybridomas
- Continuous Cell Lines
- Recombinant Cell Line
By Product
- Equipment
- Media
- Reagent
By Application
- Drug Discovery
- Bioproduction
- Tissue Engineering
Competitive Strategy and Development
- Trending Topics: Single Cell Sorting, Cell Line Development Workflow, Recombinant Proteins, Cell Line Development for Biologics, Master Cell Banking, Cell Line Engineering and Selection, Process Development, Cell Line Engineering.
Global Headlines on Cell Line Development Market
- Abzena launched new cell line development platforms
- Lonza launched GS Effex cell line for the development of therapeutic antibodies with increased potency
- Cytiva strengthened cell line development with CEVEC acquisition
Get Flat 30% Discount on purchase of Cell Line Development Market Research Report with 10% extra customization: https://www.theinsightpartners.com/buy/TIPHE100001196/
Regional Market Analysis –
- The Asia Pacific cell line development market is expected to reach US$ 2,828.53 million in 2027 from US$ 993.09million in 2019. The market is estimated to grow with a CAGR of 14.1% from 2020-2027. The growth of this market is estimated to grow owing to key driving factors such as the high growth in investments from the government in development of cell line and a rising development of the biotechnology sector.
- The Europe cell line development market is expected to reach US$ 3,187.57 million in 2027 from US$ 1,214.01million in 2019. The market is estimated to grow with a CAGR of 13.0% from 2020-2027. The growth of this market is estimated to grow owing to key driving factors such asthe increasing government participation in the cell line development market and an upsurge in the development of the biotechnology industry.
- The North America cell line development market is expected to reach US$ 3,849.54 million in 2027 from US$ 1,401.23million in 2019. The market is estimated to grow with a CAGR of 13.6% from 2020-2027. The growth of this market is estimated to grow owing to key driving factors such as the high rise in the number of cancer cases across North America and the increasing development in the biotechnology sector.
Conclusion
The cell line development market is experiencing significant growth, driven by increasing demand for biopharmaceuticals and advancements in biotechnology. This market involves creating cell lines to produce therapeutic proteins, vaccines, and monoclonal antibodies. Key factors fueling market expansion include the rising prevalence of chronic diseases, the growing focus on personalized medicine, and the need for efficient drug development processes. Moreover, technological innovations such as CRISPR and other gene-editing tools enhance the precision and efficiency of developing stable cell lines. The market is also supported by increasing investments from pharmaceutical and biotechnology companies, alongside collaborations with academic institutions. Geographically, North America holds a substantial share due to robust research infrastructure. Asia Pacific is emerging as a key region due to its expanding research activities and cost-effective development solutions. Overall, the cell line development market is poised for continued growth, projected to reach substantial valuations in the coming years.
More Trending Latest Research Life Sciences Research Reports by The Insight Partners –
Cell Line Development Serum Market Size and Growth 2031
Recombinant Proteins Market Size and Forecasts 2021 – 2031
Drug Discovery Informatics Market to 2031 – Growth and Trends
Drug Discovery Services Market Size, Growth Drivers and Future Outlook
AI for Drug Discovery Market Size and Forecasts 2021 – 2031
Bioproduction Market Size Report | Global Share & Growth Outlook 2030
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person:
Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Website – https://www.theinsightpartners.com/
